Italy 2025 CBD Ban: What’s Legal and What’s Not (September 2025 update)
In a sweeping move that’s shaken Italy’s CBD market, the April 2025 Decree-Law 48/2025 reclassified cannabidiol extracted from hemp flowers as a narcotic, criminalizing the sale and possession of oral and flower-based CBD products unless prescribed by a doctor. This decree, introduced under emergency powers and later converted into law, triggered sharp criticism from legal experts and threatened Italy’s €2 billion hemp sector and about 23,000 jobs. By targeting low-THC hemp derivatives and sidestepping European Union guidelines on CBD legality in Italy, the new rules have placed Italy at odds with EU law and its own constitutional principles.
Initially supported by the Lazio Regional Administrative Court, the ban was seen as one of Europe’s harshest stances against CBD. However, a June 2025 Parma court ruling challenged this crackdown, holding that low-THC hemp flowers and derivatives can remain legal under EU law in that specific case. As Italy’s stance collides with European trade and health rules, the future of the ban hangs in the balance, with mounting pressure from both the EU and domestic courts.
What the Law Says: CBD Now a Narcotic
The 2025 CBD crackdown in Italy, known as the Italy CBD ban 2025, was pushed through via Decree-Law No. 48/2025 (the “Security Decree”) under emergency powers and later converted into law, criminalizing the sale and commercial handling of oral and flower-based CBD products, even those from certified low-THC industrial hemp (Reuters, June 2025). The measure brings hemp inflorescences and derivatives (including resins, oils and extracts) under Italy’s narcotics framework, imposing restrictions comparable to high-THC cannabis under Italy’s CBD flower ban.
This sweeping ban was initially upheld by the Lazio Regional Administrative Court, which dismissed industry appeals in April 2025. However, the legal landscape shifted with a June 2025 Parma court ruling, which in that specific case rejected the government’s classification of hemp flowers as narcotics and reaffirmed EU protections for low-THC products.
Under Article 18 of Decree-Law 48/2025, only prescription-based pharmaceutical use of oral CBD is permitted, effectively eliminating over-the-counter and wellness access to ingestible CBD products across the country (Reuters, June 2025). While the Parma ruling has created a significant legal contradiction, national enforcement of the ban remains in place following conversion of the decree into law.
The Economic Fallout: A Billion-Euro Sector at Risk
Italy’s decision to ban non-prescription flower-based and ingestible CBD products has had a devastating effect on its once-thriving hemp industry. The ban, targeting low-THC hemp flowers and CBD-based oral/inflorescence-derived products, directly threatens a sector previously considered one of Europe’s most promising cannabis markets.
According to industry estimates, the Italian hemp market was valued at roughly €2 billion—including both direct and indirect impacts—and supported over 23,000 full-time jobs. The abrupt ban has forced thousands of small farmers, processors, and retailers into legal limbo or outright closure.
Advocacy groups like Canapa Sativa Italia have condemned the ban as unconstitutional and economically disastrous, warning it could funnel demand into the black market. Rural communities and small businesses, once buoyed by the sustainable hemp trade, are now especially vulnerable to economic hardship and criminalization.
Clashing with the EU?
Italy’s aggressive stance on CBD has put it in direct conflict with the broader European Union framework, which generally permits the sale of low-THC hemp-derived products. By classifying CBD and related cannabinoids as narcotics, Italy’s 2025 decree openly challenges EU law.
The European Commission has formally requested clarification from Italy, triggering a 90-day evaluation period to assess whether the ban violates the EU’s internal market rules. Under these principles, member states cannot unilaterally block the free movement of agricultural and industrial hemp products without scientific evidence of health risks.
Legal experts caution that Italy’s hardline approach under the Italy CBD ban 2025 could fracture the EU’s unified regulatory stance on hemp and cannabinoids. The 2020 ECJ ruling already established that CBD is not a narcotic under EU law, underscoring the contradiction between Italy’s ban and the EU’s principles for CBD legality in Italy. National deviations, like Italy’s decision to treat CBD flower and oil as narcotics, must be scientifically justified. If Italy fails to align its policy with EU standards, the ban could become a test case for the limits of national control over CBD in Italy in 2025 and other cannabinoid products within the single market.
Recommendation: What Can Businesses Do?
Even as Italy’s restrictive CBD ban faces growing legal challenges, businesses still have a narrow path to remain active in the Italian market. One practical option is to register topical-only products, but this is viable only where the cannabinoid ingredient complies with EU cosmetics rules, for example, THC-free CBD that is not obtained from cannabis resin/flowers (e.g., synthetically produced CBD) and meets all requirements under Regulation (EC) No 1223/2009. Using CBD extracted from resin/inflorescences is not permitted in EU cosmetics lists, and in Italy, flower-derived derivatives are also restricted under the Security Decree.
Companies can continue operating lawfully in Italy by focusing on topical-only uses that avoid direct conflicts with national drug classifications, and by steering clear of flower/resin-derived CBD. However, it’s crucial to avoid any medical or wellness claims and to complete the usual compliance steps (CPNP notification, PIF, GMP-like quality controls) while monitoring the ongoing SCCS safety review work on CBD in cosmetics.
For many CBD businesses, topical cosmetics built around compliant (e.g., synthetic) CBD or non-cannabinoid hemp ingredients (like hemp seed oil) offer a practical interim solution, keeping their presence alive until ongoing legal and political battles and the European Commission’s scrutiny of Italy’s measures create a clearer regulatory pathway.
Summary: What Italy’s CBD Ban Means
Italy’s 2025 CBD ban marks one of Europe’s most dramatic regulatory shifts. It reclassifies hemp-flower derivatives (including oral CBD extracted from the plant) as narcotics and outlaws non-prescription oral and flower-based hemp products. Initially upheld by the Lazio Regional Court in April 2025, the ban has placed over 23,000 jobs and €2 billion in economic value at risk; an existential threat to Italy’s once-flourishing hemp sector. (Reuters, June 2025).
However, a June 2025 Parma court ruling has challenged this hardline approach, in that specific case affirming EU protections for low-THC hemp and reopening the legal fight. With the European Commission scrutinizing Italy’s restrictions and asking for explanations, but no formal infringement procedure opened as of September 2025, the future of the ban hangs in the balance.
Key Takeaways
- Hemp-flower derivatives and oral CBD from hemp are treated as narcotics under Italy’s 2025 measures.
- Oral and flower-based CBD products are banned unless prescribed.
- The Lazio court upheld the ban, but the Parma ruling (case-specific) contradicts it.
- Over 23,000 jobs and ~€2 billion in value are at risk (industry estimates).
- Italy’s law clashes with EU norms, under Commission scrutiny (not yet a formal infringement case).
👉 Read our updated guides for the current legal status of CBD in Italy and how importation rules have evolved.
👉 Explore how Slovenia’s new cannabis reform could unlock fresh opportunities for CBD businesses here.
About us
At Essentia Pura, we specialize in manufacturing high-quality white-label and private-label CBD products, helping businesses launch their own unique CBD brands. With cutting-edge hemp extraction methods and a commitment to compliance and quality, we support companies in the nutraceutical, pharmaceutical, and cosmetic industries. Whether you’re looking for ready-to-market formulations or custom solutions, we’re here to help you succeed in the growing CBD market.
